Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Stable prostaglandin E gels utilizing colloidal silicon dioxide as a gel-forming agent|
|Abstract:||The present invention provides an improved class of stable gels of prostaglandin E compounds prepared from solutions of prostaglandin E compounds in a pharmaceutically acceptable, stabilizing organic solvent, e.g., triacetin, gelled by the addition of colloidal silicon dioxide.|
|Inventor(s):||Johnson; Brian S. (Crawley, GB)|
|Assignee:||The Upjohn Company (Kalamazoo, MI)|
|Patent Claims:||1. In a stable dosage form of PGE.sub.2 consisting essentially of PGE.sub.2 in triacetin, an improvement which comprises: colloidal silicon dioxide (CSD) as a gel forming additive thereto in a concentration by weight of CSD in said stable dosage form from about not less than 8 percent to about not more than 15 percent.|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.